• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home Genetics

Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer

byKassandra McFarlaneandSze Wah Samuel Chan
November 2, 2021
in Genetics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Median progression-free survival was 56.0 months in the olaparib group and was 13.8 months in the placebo group.

2. 5-year progression-free survival was 48% in the olaparib group and 21% in the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Newly diagnosed advanced ovarian cancer has a high likelihood of relapse and associated mortality as a result. New treatments are needed in order to prolong survival in these patients. Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor and tumour-cells with BRCA mutations are incapable of repairing DNA damage secondary to PARP inhibition, thereby leading to tumour-cell death. This study describes the outcomes on progression-free survival (PFS), 5 year PFS, and safety of olaparib as compared to placebo in patients with advanced ovarian cancer who had previously responded to platinum-based chemotherapy. Median PFS in the olaparib group was 56.0 months and in the placebo group, it was 13.8 months. PFS at 5 years was 21% in the placebo group and 48% in the olaparib group. Safety was assessed in every patient that received study treatment (either placebo or drug). 21% of patients in the olaparib group experienced serious adverse events (AEs) while 13% did in the placebo group. The most common serious AEs were anemia, neutropenia, and fatigue. One limitation of this study is the requirement for patients to have had either partial or complete response to previous chemotherapy. The results from this are therefore not applicable to patients who did not respond to initial treatment. Overall, olaparib is a potential maintenance treatment option for patients with newly diagnosed advanced ovarian cancer.

Click to read the study in Lancet Oncol

Relevant Reading: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

RELATED REPORTS

Maintenance Olaparib Rechallenge in Platinum-Sensitive Relapsed Ovarian Cancer

Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer

Olaparib improves the quality of life for metastatic castration-resistant prostate cancer patients

In-Depth [randomized controlled trial]: This phase 3, double-blinded and randomized control trial was conducted across multiple centres in 15 countries. 391 patients were randomly assigned by 2:1 allocation to receive either olaparib (n=260) or placebo (n=131); one placebo-assigned patient withdrew prior to study start. Criteria for eligibility included adult patients with a new diagnosis of advanced endometrioid ovarian cancer with a BRCA1 and/or 2 mutation that had partially or completely responded to previous platinum-based chemotherapy, and were expected to live at least 16 weeks. The impact on PFS, 5-year PFS, and safety of olaparib compared to placebo were described. Median PFS on olaparib was 56.0 months (95% confidence interval (CI), 41.9 months – not reached) as compared to 13.8 months on placebo (95% CI, 11.1-18.2 months) (hazard ratio (HR) 0.33 (95% CI, 0.25-0.43). PFS at 5 years was 21% (95% CI, 14-28%) in the placebo group and 48% (95% CI, 41-55%) in the olaparib group. PFS benefit of olaparib was consistent between both higher- and lower-risk subgroups. Each patient that received a dose of olaparib or placebo was assessed for AEs. Serious AEs were recorded in 21% of patients in the olaparib group and 13% of the placebo group. Anemia, neutropenia, and fatigue were the most common. Anemia was the most common AE due to treatment; 7% of the olaparib and 0% of the placebo group were affected. Dose interruption or reduction was preferable to discontinuation for managing AEs.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: brcaOlaparibPARP (polyadenosine diphosphate-ribose polymerase) inhibitors
Previous Post

Running may increase injury risk in overweight children

Next Post

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

RelatedReports

The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Oncology

Maintenance Olaparib Rechallenge in Platinum-Sensitive Relapsed Ovarian Cancer

October 16, 2023
Oncology

Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer

January 16, 2023
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Olaparib improves the quality of life for metastatic castration-resistant prostate cancer patients

March 27, 2022
#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018
StudyGraphics

#VisualAbstract: Trends in positive BRCA results among older women between 2008 to 2018

December 16, 2020
Next Post
Social networks play key roles in parental vaccination decisions

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Antenatal antibiotic exposure associated with increased risk of childhood asthma

No significant increased risk of bladder cancer with pioglitazone use

Quality improvement initiative in pediatric emergency departments improves opioid prescribing practices

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.